Immutep Limited is an Australian clinical-stage immunotherapy company whose ADSs trade on Nasdaq under IMMP. It is a pioneer in LAG-3 (Lymphocyte Activation Gene-3) biology, developing therapies that either stimulate the immune system against cancer or suppress it in autoimmune disease. Unlike a typical large-cap, IMMP does not have a clean, current analyst consensus.
After the company's TACTI-004 Phase III trial of its lead asset eftilagimod alfa (efti) in first-line non-small cell lung cancer was discontinued for futility on March 13, 2026, the ADS fell roughly 83% in a single session, and most coverage was downgraded or withdrawn. In September 2026 the company completed a 1-for-20 reverse split of its ADSs (changing the ratio from one ADS per 10 ordinary shares to one per 200), which makes older price targets difficult to compare directly.
What remains is thin: a single Buy from Maxim Group, whose pre-split $1.50 target appears as a mechanically split-adjusted $30 in some quote feeds — an outlier that is not a usable consensus. Because no meaningful multi-analyst aggregate exists, the $4.00 central target used here is a fallback, drawn from technical and public-discussion context: a round-number resistance level roughly 20% above the latest close, just above the stock's post-split intraday high near $3.49. It is a directional objective, not a published price forecast.
The ADS closed at $3.34 on November 6, 2026, giving the company a market capitalization of only about $24.6 million. Reaching $4.00 would require a move of about $0.66, or roughly 20% — a modest move in percentage terms, but one that would have to be driven almost entirely by sentiment and pipeline news, because IMMP is pre-commercial and generates revenue mainly from grants, R&D tax incentives, and interest rather than product sales.
The company's path runs through its remaining clinical programs. Management has said it intends to focus registration-directed development of efti on head and neck squamous cell carcinoma (HNSCC) in patients with low PD-L1 (CPS <1) and on the neoadjuvant soft tissue sarcoma setting, with new trials targeted to start in the second half of calendar 2027. Meanwhile, IMP761, an agonist LAG-3 antibody for autoimmune disease, delivered positive Phase I data showing statistically significant, exposure-dependent inhibition of T-cell-driven immune responses. These readouts, rather than near-term earnings, are what would need to re-rate the shares.
Following the reverse split, the ADS has traded in a range roughly between $2.66 and $3.49, with the $3.49 area acting as near-term resistance. A move toward $4.00 would require clearing that level and the $4.00 round-number zone, which could then become a fresh support area if reclaimed. Below, the $3.00–$2.66 band represents the primary support zone established since the September 2026 split.
With no credible multi-analyst 12-month consensus available, the $4.00 objective carries no firm time horizon. Investors should monitor the initiation and enrollment of the refocused efti registration studies, further IMP761 data, cash runway updates, quarterly activities reports, any resolution or escalation of the class action litigation, and continued Nasdaq listing compliance. Clinical and regulatory news, rather than earnings, will drive the stock.
For investors who want a systematic way to track developments like these, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than scanning charts manually. Consider exploring these signals as a complement to fundamental research on IMMP.
The question of whether IMMP can reach $4.00 is best understood as a modest, sentiment-driven recovery objective rather than a valuation-based forecast. The roughly 20% move required is not large, but this is a pre-commercial biotech whose investment case was damaged by a failed Phase III trial, now compounded by litigation and a reverse split. A cash-rich balance sheet and a diversified pipeline — particularly IMP761 — offer a plausible support narrative, while execution risk on the refocused efti program and thin, volatile trading are the principal obstacles. Because no meaningful analyst consensus exists, the $4.00 level should be treated as a technical benchmark to watch, not a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IMMP has been loosely correlated with ELOX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMP jumps, then ELOX could also see price increases.
| Ticker / NAME | Correlation To IMMP | 1D Price Change % | ||
|---|---|---|---|---|
| IMMP | 100% | -8.95% | ||
| ELOX - IMMP | 47% Loosely correlated | -4.52% | ||
| GPCR - IMMP | 38% Loosely correlated | +1.49% | ||
| BCRX - IMMP | 38% Loosely correlated | -1.31% | ||
| HIND - IMMP | 36% Loosely correlated | -3.14% | ||
| LIMN - IMMP | 34% Loosely correlated | +2.59% | ||
More | ||||